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Background: The Prospective Epidemiological Research on Functioning Outcomes Related 
to Major Depressive Disorder (PERFORM) study has been initiated to better understand the 
course of a depressive episode and its impact on patient functioning. This analysis aimed to 
identify sociodemographic and clinical factors associated with failure to achieve remission at 
month 2 after initiating or switching antidepressant monotherapy and with subsequent relapse 
at month 6 for patients in remission at month 2.
Materials and methods: This was a 2-year observational cohort study in 1,159 outpatients 
aged 18–65 years with major depressive disorder initiating or undergoing the first switch of 
antidepressant monotherapy. Factors with P0.20 in univariate logistic regression analyses 
were combined in a multiple logistic regression model to which backward variable selection 
was applied (ie, sequential removal of the least significant variable from the model and recom-
putation of the model until all remaining variables have P0.05).
Results: Baseline factors significantly associated with lower odds of remission at month 2 
were body-mass index 30 kg/m2 (OR 0.51), depressive episode 8 weeks (OR 0.51), being in 
psychotherapy (OR 0.51), sexual dysfunction (OR 0.62), and severity of depression (OR 0.87). 
Factors significantly associated with relapse at month 6 were male sex (OR 2.47), being married 
or living as a couple (OR 2.73), residual patient-reported cognitive symptoms at 2 months (OR 
1.12 per additional unit of Perceived Deficit Questionnaire-5 score) and residual depressive 
symptoms at 2 months (OR 1.27 per additional unit of Patient Health Questionnaire-9 score).
Conclusion: Different factors appear to be associated with failure to achieve remission in 
patients with major depressive disorder and with subsequent relapse in patients who do achieve 
remission. Patient-reported cognitive dysfunction is an easily measurable and treatable charac-
teristic that may be associated with an increased likelihood of relapse at 6 months in patients 
who have achieved remission.
Keywords: major depressive disorder, remission, relapse, patient-reported cognitive 
dysfunction
Introduction
Major depressive disorder (MDD) is a chronic and recurring condition that affects 
more than 120 million people worldwide and ranks among the top ten causes of global 
disability.1,2 Patients with MDD report substantial deficits in daily functioning3 that 
equal or exceed those associated with other severe chronic medical conditions, such 
as diabetes and congestive heart failure.4 Multiple domains of functioning may be 
impaired;4 consequently, MDD can have a significant impact on both quality of life 
and work productivity.5,6
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In terms of clinical management of MDD, the primary 
objective is to achieve remission. However, despite thera-
peutic advances, a considerable proportion of patients fail 
to achieve this goal. Meta-analyses of results of controlled 
clinical trials have generally shown remission rates of 
30%–50% after 6–8 weeks of treatment with currently 
available antidepressants.7–12 Remission rates are even lower 
in routine practice settings. In the US STAR*D study – a 
large trial designed to assess the efficacy of sequential 
acute treatments for MDD – only 30%–40% of patients 
achieved remission after adequate treatment with a first-
line antidepressant.13,14 In addition, approximately a third of 
patients failed to achieve remission after trials of as many 
as four different antidepressants.14 A 12-week remission 
rate of 31.4% was reported in the South Korean Clinical 
Research Centre for Depression study.15 Beyond its clinical 
consequences, failure to achieve remission in MDD is associ-
ated with subsequently higher annual health-care resource 
utilization and expenditure.16–19
For patients who have achieved remission, the objec-
tive of clinical management is to prevent relapse. However, 
prevention of relapse in patients who achieve remission is 
also a challenge for current treatments. In STAR*D, the 
6-month relapse rate was 34%–83%, depending on the phase 
of treatment.13 Patients who relapse within 6 months of remis-
sion have been shown to have a far worse course of depression 
over the next 5 years than those who do not relapse within this 
period of time, as indicated by a significantly greater propor-
tion of time spent with higher levels of severity of depressive 
symptoms and fewer asymptomatic weeks.20
Awareness of sociodemographic or clinical factors 
that may be associated with failure to achieve remission in 
patients with MDD or with an increased risk of subsequent 
relapse in patients who do achieve remission may help to 
improve clinical management by enabling identification 
of patients who may require more intensive follow-up and 
care. Sociodemographic factors that have previously been 
reported to be associated with failure to achieve remission 
of MDD include sex,21,22 educational level,21,23 employment 
status,21,23 and marital status;24 clinical factors include depres-
sion severity in the acute phase,25,26 concomitant mental or 
chronic medical disorders,21,22 and lower functioning and 
quality of life at baseline.21,24 Factors that have been reported 
to be associated with relapse in patients with MDD include 
chronicity (ie, presence of previous depressive episodes)27,28 
and presence of residual mood symptoms.29 Many studies 
have been undertaken to identify factors that may be asso-
ciated with poor treatment outcomes in MDD; however, 
the majority of these have been in highly selected patient 
populations, which may limit generalization of the findings 
to routine clinical practice.
The Prospective Epidemiological Research on Function-
ing Outcomes Related to Major Depressive Disorder (PER-
FORM) study is an observational cohort study initiated to 
better understand the course of a depressive episode and its 
impact on patient functioning over a 2-year period in out-
patients with MDD in real-world settings in five European 
countries. This paper reports planned analyses undertaken 
to examine potential sociodemographic or clinical factors 
associated with failure to achieve remission at month 2 and 
with subsequent relapse at month 6 for patients in remission 
at month 2. Factors explored included those previously identi-
fied in the literature and others, such as cognitive symptoms, 
which have been identified more recently as relevant in the 
course of depression and thus have been less extensively 
studied to date.30,31
Materials and methods
study design
This was a 2-year multicenter, prospective, noninterventional 
cohort study in outpatients aged 18–65 years with a cur-
rent diagnosis of MDD (Diagnostic and Statistical Manual 
of Mental Disorders [DSM]-IV-TR) enrolled by either a 
primary care physician or a psychiatrist in France, UK, 
Spain, Germany, and Sweden. This study is registered with 
ClinicalTrials.gov (NCT01427439). Enrolled patients were 
either initiating antidepressant monotherapy or undergoing 
their first switch of antidepressant for a new episode of major 
depression, with the choice of antidepressant used based 
on the clinical judgment of the treating physician. Patients 
receiving antidepressant combination therapy at the time of 
the initial consultation and patients with schizophrenia or 
other psychotic disorders, bipolar disorder, substance depen-
dence, mood disorders due to a general medical condition or 
substances, dementia, or other neurodegenerative diseases 
significantly impacting cognitive functioning were excluded 
from study entry. Pregnant women and women 6 months’ 
postpartum were also excluded.
ethics approval and consent to 
participate
Ethical approval was obtained for each study site before 
study initiation following country regulations regarding 
observational studies:
•	 France: French health authority (ANSM, previously 
called AFSSAPS), advisory committee on information 
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processing in material research in the field of health 
(CCTIRS), French data-protection agency (CNIL), 
French National Medical Council (CNOM) Ethics 
Committee (CPP Ile de France II); 102 physicians/sites 
included
•	 Germany: Munich Ethics Committee, local ethics com-
mittees, including Hamburg, Rheinland-Pfalz, Sachsen, 
and Westfalen-Lippe ethics committees and others; 
47 physicians/sites included
•	 Spain: Agencia Española del Medicamento y Productos 
Sanitarios (AEMPS), Comités Eticos de Investigaciones 
Clinicas (CEIC), Comunidades Autónomas (CCAA) of 
14 regions; 46 physicians/sites included
•	 Sweden: Uméå Ethics Committee; 22 physicians/sites 
included
•	 UK: Medical Research and Ethics Committee (MREC), 
National Institute for Health Research (NIHR), and local 
submissions; 65 physicians/sites included.
All patients provided written informed consent for 
participation.
study assessments and data collection
Study assessments and data collection occurred during 
routine visits within the normal course of care at baseline, 
2 months (±3 weeks), and 6 months (±1 month), after which 
data were collected approximately every 6 months up to 
2 years. Patient characteristics recorded included demo-
graphic information, history of MDD, characteristics of 
the current episode of depression, MDD management and 
resource use, and the presence of any other mental disorder 
or functional syndrome.
Clinical severity of depression was assessed at all visits 
by patients using the nine-item Patient Health Question-
naire (PHQ-9)32 and by all participating investigators using 
the Clinical Global Impressions–severity of illness scale 
(CGI-S).33 The Montgomery–Åsberg Depression Rating 
Scale (MADRS)34 was also administered when patients were 
recruited by psychiatrists. Patient-reported cognitive function 
was assessed using the five-item Perceived Deficit Question-
naire (PDQ-5), which assesses subjective cognitive symp-
toms (impairments in memory, concentration, and executive 
function) over the past 4 weeks.35,36 Total score range is 0–20, 
with higher scores reflecting greater impairment.
Psychiatrists also assessed the severity of anxiety symp-
toms using the Hamilton Anxiety Rating Scale.37 Other 
patient-reported questionnaires administered included the 
Sheehan Disability Scale,38 the Work Productivity and 
Activity Impairment Questionnaire,39 the 12-item Short-Form 
Health Survey (SF-12),40 the EuroQol questionnaire (EQ-5D 
three-level version; in UK patients only),41 the Arizona 
Sexual Experiences Scale,42 and the four-item Morisky–
Green Medication Adherence Scale.43
Outcomes
The primary definition of remission at the 2-month visit was 
PHQ-9 total score 9.32 If PHQ-9 score was missing, then 
MADRS total score was used for patients recruited by psy-
chiatrists; remission was defined as a MADRS score 10.44,45 
If MADRS score was missing, then remission was defined as 
a CGI-S score 2.46 For patients in remission at 2 months, 
relapse at the 6-month visit was defined as: (i) treatment 
modification (switch or combination) for lack of efficacy 
at the 6-month visit;47 or (ii) PHQ-9 total score 10 at the 
6-month visit,32 or MADRS total score 22 at the 6-month 
visit if PHQ-9 was missing,48 or CGI-S score 4 at the 
6-month visit if PHQ-9 and MADRS were missing.48 Relapse 
status was classified as ambiguous for patients who met 
criteria for both remission and relapse at month 6 or who 
were neither remitters nor relapsers at month 6 (eg, MADRS 
score of 11–21 if PHQ-9 was missing or CGI-S score of 3 if 
PHQ-9 and MADRS were missing).
statistical analysis
The population for analysis comprised all patients who met 
study inclusion criteria and for whom at least one postbase-
line assessment was recorded. Clinically relevant variables 
recorded at baseline were tested in univariate logistic regres-
sion analyses for association with failure to achieve remission 
at month 2. Clinically relevant variables recorded at baseline 
and/or at or up to month 2 were tested in univariate logistic 
regression analyses for association with subsequent relapse 
at month 6 in patients who achieved remission at month 2. 
The variables included in these univariate analyses were 
selected based on literature review and clinical evaluation 
(Table 1). Variables with P0.20 in the univariate analyses 
were then combined in a multiple logistic regression model to 
which backward variable selection was applied (ie, sequential 
removal of the least significant variable from the model and 
recomputation of the model until all remaining variables 
had P0.05). Four factors were forced into the model as 
adjustment variables because they were identified as poten-
tial confounders: country, age, sex, and PHQ-9 total score 
(at baseline for the remission analysis and at month 2 for the 
relapse analysis).
Results are presented as ORs with 95% CIs. By default, 
ORs for assessment scales and for continuous outcomes are 
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given per additional unit. To account for the differences in 
metrics between scales, ORs for assessment scales were also 
estimated per additional 0.5 SD to provide a standardized 
measure and enable comparisons between scales. Supportive 
analyses were performed by using a forward-selection 
process instead of backward selection. In addition, for the 
analysis of factors associated with relapse, alternative defini-
tions for remission and relapse were used to investigate the 
effect of the PHQ-9 thresholds applied in the study. Alterna-
tive definitions included reducing the cutoff used to define 
remission, placing MADRS before PHQ-9 in the composite 
definition of remission, increasing the cutoff used to define 
relapse, and imposing a defined minimum change in PHQ-9 
score. These later analyses were conducted using the final 
model identifying factors associated with relapse at month 6 
for patients in remission at month 2 obtained by backward 
selection. All statistical analyses were performed using SAS 
version 9.2 (SAS Institute, Cary, NC, US).
Results
Patients
A total of 1,895 patients were screened, of whom 1,402 were 
enrolled in the study. The first patient was screened on Feb-
ruary 25, 2011, and the last patient completed the study on 
February 19, 2015. In all, 1,159 (82.7%) patients were included 
in the population for analysis. Reasons for exclusion from the 
analysis population were violation of at least one of the inclu-
sion and/or exclusion criteria at baseline (n=167) or lack of 
Table 1 Variables selected for univariate analyses to identify factors associated with remission at month 2 and relapse at month 6 for 
patients in remission at month 2
Remission Relapse
sociodemographic factors country
age49
sex21,22
Tobacco use21
educational level21,23
Body-mass index50
Marital status24
employment status21,23
living area
at least one important life event
country51
age52
sex27
Tobacco use53
educational level54
Body-mass index (M2)27,55
Marital status (M2)54
employment status (M2)
at least one important life event (M2)
Patient history Depressive episode before the visit56
Previous depressive episode56
Time since beginning of this depressive episode25
Previous depressive episode27,28
comorbidities at least one other concomitant mental disorder21,57
at least one chronic medical condition21,22
Chronic pain or fibromyalgia22
at least one anxiety symptom/disorder21,25,56,58
at least one concomitant mental disorder53,59,60
at least one chronic medical condition
Chronic pain or fibromyalgia51
at least one anxiety symptom/disorder (M2)25,61,62
resource use and treatment patterns Physician specialty
current psychotherapy
sick leave within past 12 months
hospitalization for depression over past 12 weeks63
switch of antidepressant
Physician specialty
Previous or current psychotherapy
Treatment stopped between baseline and M2
sick leave (pre-M2)
hospitalization for depression (pre-M2)
switch of antidepressant (pre-M2)
MMas-4 score (M2)64
Treatment line (M2)
Disease characteristics Prior suicide attempt23,63
PhQ-9 total score25,26,56
cgi-s score25,26
PDQ-5 total score
WPai-shP score21,65
sF-12 – Pcs score21,24
sF-12 – Mcs score21,24
sexual dysfunctiona
suicide attempt (pre-M2)60
PhQ-9 total score (M2)51,66
cgi-s score (M2)51,66
PDQ-5 total score (M2)
WPai-shP score (M2)67
sF-12 – Pcs score (M2)67
sF-12 – Mcs score (M2)67
sexual dysfunctiona (M2)
Notes: aPatients were categorized as having sexual dysfunction if their total aseX score was 19 or their score was 5 for one item or 4 for at least three items. Variables 
were selected based on literature review and clinical evaluation. all variables were assessed at baseline, unless otherwise indicated.
Abbreviations: aseX, arizona sexual experience scale; cgi-s, clinical global impressions–severity of illness; M2, month 2; Mcs, mental component summary; MMas-4, 
4-item Morisky–Green Medication Adherence Scale; PCS, physical component summary; PDQ-5, 5-item Perceived Deficit Questionnaire; PHQ-9, 9-item Patient Health 
Questionnaire; Pre-M2, prior and up to M2 (any time before baseline, at baseline, or between baseline and M2); sF-12, 12-item short-Form health survey; WPai-shP, Work 
Productivity and Activity Impairment–specific health problem.
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postbaseline data (n=101, including 76 who met the inclusion 
criteria at baseline). The majority of patients were enrolled and 
followed up by primary care physicians (n=969; 83.6%). At the 
start of the study, 78.7% of patients were initiating antidepres-
sant treatment and 21.3% were switching antidepressant; the 
treatment status of two patients was unknown.
Remission status was available for 1,112 of the 
1,120 patients who attended a month 2 visit (99.3%). Of 
these 1,112 patients, 330 were in remission (29.7%). Of 
the 330 patients in remission at month 2, 300 had known 
relapse status at month 6 (90.9%). Of those, 59 (19.7%) had 
relapsed at month 6, 226 (75.3%) were in sustained remis-
sion, and remission status was ambiguous for 15 (5.0%). 
Tables 2 and 3 present baseline data for the different study 
subpopulations.
Factors associated with failure to achieve 
remission at month 2
Statistically significant results (P0.05) were observed for 
18 of the 30 factors of interest included in the univariate 
analyses (Table 1): switch of antidepressant, body-mass index 
(BMI), tobacco use, educational level, time since beginning 
of this depressive episode, at least one other concomitant 
mental disorder, chronic pain or fibromyalgia, hospitalization 
for depression during the 12 weeks before baseline, suicide 
attempt before baseline, sick leave during the 12 months 
before baseline, current psychotherapy, PHQ-9 total score, 
PDQ-5 total score, CGI-S score, percentage activity impair-
ment due to problem, SF-12 physical component summary 
(PCS), SF-12 mental component summary (MCS), and sexual 
dysfunction. Living area and at least one chronic medical con-
dition were not statistically significant in univariate analyses; 
however, since the P-values for these factors were below 
0.20, they were also included in the multivariate analysis.
In addition to the four forced adjustment factors (coun-
try, age, sex, and PHQ-9 total score at baseline), the final 
multivariate analysis model retained four factors with 
P0.05 from the backward-selection process: BMI, time 
since beginning of this depressive episode, current psycho-
therapy, and sexual dysfunction (Table 4). Among the forced 
factors, country and PHQ-9 total score were statistically 
significant.
Table 2 Baseline sociodemographic characteristics for subsets of patients by remission status at month 2 and by relapse status at 
month 6 in those who achieved remission at month 2
Characteristic Remission status at  
month 2
Relapse status at month 6 in those who 
achieved remission at month 2
In remission 
(n=330)
Not in remissiona 
(n=782)
Total  
(n=1,112)
Relapsed 
(n=59)
Not relapsed 
(n=241)
Total  
(n=300)
age, mean ± sD (years) 45.3±11.9 44.1±11.9 44.4±11.9 43.9±12.1 45.7±11.7 45.3±11.8
Female (%) 72.7 73.2 73.1 67.8 74.3 73.0
Marital status (%)
single
Married/couple
Divorced/separated
Widowed
20.0
60.0
17.0
3.0
22.3
57.9
16.8
3.1
21.6
58.5
16.8
3.1
15.3
74.6
8.5
1.7
19.5
58.5
18.7
3.3
18.7
61.7
16.7
3.0
education (%)
No degree or diploma
elementary school
high school
Non-university degree
University degree
2.7
21.2
36.4
14.2
25.5
4.9
26.6
37.4
12.9
18.2
4.2
25.0
37.1
13.3
20.3
1.7
32.2
25.4
13.6
27.1
2.9
19.5
37.3
14.9
25.3
2.7
22.0
35.0
14.7
25.7
living area (%)
rural
Urban
36.1
63.9
30.1
69.9
31.9
68.1
39.0
61.0
36.5
63.5
37.0
63.0
Work status (%)
Paid employment or self employed 67.9 66.4 66.8 67.8 68.9 68.7
Tobacco use (%) 29.4 35.7 33.8 30.5 28.6 29.0
BMI classification (%)
Normal weight
Overweight
Obese
50.9
30.3
18.8
45.1
28.7
26.2
46.8
29.2
24.0
42.4
37.3
20.3
52.3
29.5
18.3
50.3
31.0
18.7
Note: ainformation was missing for one patient for each of age, sex, tobacco use, marital status, living area, and educational level, and for four patients regarding BMi.
Abbreviation: BMi, body-mass index.
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The odds of achieving remission at month 2 were signifi-
cantly lower for obese patients (BMI 30 kg/m2), patients with 
a longer time since the beginning of the depressive episode 
(8 weeks vs 4 weeks), patients who were in psychotherapy 
at the beginning of the study, and patients who had sexual 
dysfunction. The odds of achieving remission at month 2 
were 13% less likely when the PHQ-9 total score increased by 
1 unit (P0.001) and 30% less likely when PHQ-9 total score 
Table 3 Medical profile, functioning, and quality of life at baseline for subsets of patients by remission status at month 2 and by relapse 
status at month 6 in those who achieved remission at month 2
Characteristics of current  
depressive episode
Remission status at  
month 2
Relapse status at month 6 in 
those who achieved remission  
at month 2
In remission 
(n=330)
Not in remission 
(n=782)
Total 
(n=1,112)
Relapsed 
(n=59)
Not relapsed 
(n=241)
Total 
(n=300)
Treated with antidepressant before baseline visit (%)
Time since beginning of this depressive episode (%)
1 week
1–2 weeks
2–4 weeks
4–8 weeks
8 weeks
Significant symptoms of anxiety (%)a
symptoms treated with anxiolytics (%)
currently receiving psychotherapy (%)
Questionnaire scores, mean ± SD
PDQ-5
PhQ-9
cgi-s
MaDrs
aseX
Total score
sexual dysfunctionb (%)
16.7
3.3
7.6
25.5
18.5
45
61.2
42.6
10.3
9.6±4.5
15.1±5.6
3.9±1.1
31.8±7.4
20.3±5.5
75.4
23.8
0.8
5.1
19.3
20.9
53.9
63.2
41.6
15.9
12.1±4.4
18.7±4.8
4.3±0.9
33.0±7.1
21.9±5.8
84.4
21.7
1.5
5.9
21.2
20.2
51.3
62.6
41.9
14.2
11.3±4.6
17.6±5.3
4.2±1.0
32.7±7.2
21.4±5.7
81.8
20.3
3.4
8.5
27.1
20.3
40.7
61.0
38.5
8.5
11.6±4.2
16.6±4.1
4.1±1.0
33.3±6.2
20.8±5.3
70.8
15.8
3.3
7.5
27.5
18.3
43.3
62.7
44.3
10.0
8.9±4.4
14.7±5.8
3.9±1.2
31.6±7.7
20.2±5.5
76.5
16.7
3.3
7.7
27.4
18.7
42.8
62.3
43.2
9.7
9.4±4.5
15.0±5.6
3.9±1.2
32.0±7.4
20.3±5.5
75.3
Other current illnesses
Mental health disorders other than depression (%)
alcohol abuse or dependence
Other abuse disorders
somatoform disorders
eating disorders (anorexia, bulimia)
Other
2.7
0.3
6.4
4.8
1.2
2.3
1.5
8.7
8.7
0.3
2.4
1.2
8.0
7.6
0.5
1.7
0.0
6.8
1.7
1.7
2.9
0.4
6.2
4.6
0.8
2.7
0.3
6.3
4.0
1.0
Functional syndromes (%)
chronic pain
chronic fatigue
Fibromyalgia
Premenstrual syndrome
sleep disorders
Other
14.2
11.8
3.9
2.7
22.7
2.4
17.5
17.9
8.3
3.7
30.1
2.9
16.5
16.1
7.0
3.4
27.9
2.8
18.6
15.3
5.1
5.1
22.0
3.4
13.3
11.6
3.7
2.1
24.1
2.5
14.3
12.3
4.0
2.7
23.7
2.7
chronic medical conditions (%)
cardiovascular disease
Diabetes
cancer
rheumatoid arthritis
Neurologic disorders
Other
10.9
4.8
2.1
0.9
2.4
9.7
11.3
4.7
0.8
1.8
2.9
13.8
11.2
4.8
1.2
1.5
2.8
12.6
13.6
0.0
5.1
0.0
0.0
11.9
10.8
5.0
1.7
0.8
3.3
9.1
11.3
4.0
2.3
0.7
2.7
9.7
Previous depressive episodes
history of depression (%)
Previous episode
episode within previous 12 months of previous episode
Previous suicide attempt
57.1
23.4
8.0
56.0
25.9
16.0
56.3
25.1
13.6
61.0
27.8
16.7
55.8
24.6
5.2
56.9
25.3
7.6
Notes: n refers to the total number of patients in each subgroup; as not all patients provided data for all parameters, n is not the denominator for all percentage calculations, 
and the actual denominator varies between parameters. aPercentages refer to patients “probably” or “definitely” presenting clinically significant symptoms of anxiety according 
to physician; bpatients were categorized as having sexual dysfunction if their total aseX score was 19 or their score was 5 for one item or 4 for at least three items.
Abbreviations: ASEX, Arizona Sexual Experience Scale; CGI-S, Clinical Global Impressions–severity of illness; PDQ-5, 5-item Perceived Deficit Questionnaire; PHQ-9, 
9-item Patient health Questionnaire; MaDrs, Montgomery–Åsberg Depression rating scale.
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increased by 0.5 SD (2.6 units). As ORs cannot be interpreted 
as relative risks, these figures are provided only to gain a 
better understanding of the size of the effect.
The results of the supportive analysis using the forward-
selection process were consistent with those obtained using 
the backward-selection process (base-case analysis). In 
particular, the same factors were retained by both selection 
processes. The only factor among those initially selected that 
had a P-value between 0.05 and 0.10 when removed from the 
multivariate models during the backward-selection process 
was suicide attempt before baseline (P=0.0624) (Table S1).
Factors associated with relapse at month 6
Statistically significant results (P0.05) were observed for 
six of the 30 variables of interest selected to perform the 
univariate analyses (Table 1): marital status, PHQ-9 total 
score, PDQ-5 total score, percentage activity impairment due 
to problem, SF-12 MCS, and suicide attempt (before baseline 
or between baseline and month 2). CGI-S, SF-12 PCS, and 
switch of antidepressant (at baseline, between baseline and 
month 2, or at month 2) were not statistically significant in 
univariate analyses, but were included in the multivariate 
analysis (P0.20).
In addition to the four forced adjustment factors (country, 
age, sex, and PHQ-9 total score at month 2), the final 
multivariate analysis model retained two factors with P0.05 
from the backward-selection process: marital status and PDQ-5 
total score at month 2 (Table 5). Among the forced factors, sex 
and PHQ-9 total score were statistically significant.
Table 4 Multivariate logistic regression model for analysis of risk factors of failure to achieve remission at month 2 (backward selection)
Variable Category n/N (%) OR (95% CI) P-value
countrya France
spain
UK
sweden
germany
53/158 (33.5)
32/91 (35.2)
67/204 (32.8)
11/34 (32.4)
24/101 (23.8)
1
1.04 (0.57–1.88)
1.57 (0.93–2.62)
1.62 (0.67–3.91)
0.45 (0.24–0.85)
0.900
0.089
0.284
0.013
age Per additional year – 1.01 (0.99–1.02) 0.412
sex Female
Male
136/430 (31.6)
51/158 (32.3)
1
0.74 (0.48–1.16) 0.187
Body-mass index 30 kg/m2
30 kg/m2
156/448 (34.8)
31/140 (22.1)
1
0.51 (0.31–0.84) 0.008
Time since beginning of 
this depressive episodeb
4 weeks
4–8 weeks
8 weeks
70/165 (42.4)
34/111 (30.6)
83/312 (26.6)
1
0.60 (0.34–1.05)
0.51 (0.33–0.81)
0.073
0.004
current psychotherapy No
Yes
169/494 (34.2)
18/94 (19.1)
1
0.51 (0.28–0.93) 0.028
PhQ-9 total score Per additional unit – 0.87 (0.84–0.91) 0.001
sexual dysfunction (aseX) No
Yes
49/112 (43.8)
138/476 (29.0)
1
0.62 (0.38–0.99) 0.045
Notes: n refers to the number of patients with remission in each category; N refers to the total number of patients in each category. aglobal P=0.005; bglobal P=0.016.
Abbreviations: aseX, arizona sexual experience scale; PhQ-9, 9-item Patient health Questionnaire.
Table 5 Multivariate logistic regression model for analysis of risk factors of relapse at month 6 for patients in remission at month 2 
(backward selection)
Variable Category n/N (%) OR (95% CI) P-value
countrya France
spain
UK
sweden
germany
11/59 (18.6)
5/27 (18.5)
15/65 (23.1)
3/9 (33.3)
3/26 (11.5)
1
0.79 (0.22–2.82)
0.97 (0.36–2.64)
2.15 (0.40–11.49)
0.51 (0.12–2.22)
0.719
0.952
0.371
0.367
age Per additional year – 0.99 (0.96–1.03) 0.765
sex Female
Male
21/131 (16.0)
16/55 (29.1)
1
2.47 (1.05–5.8) 0.037
Marital status (M2) single or divorced/separated or widowed
Married or living as a couple
8/66 (12.1)
29/120 (24.2)
1
2.73 (1.05–7.12) 0.040
PhQ-9 total score (M2) Per additional unit – 1.27 (1.02–1.59) 0.030
PDQ-5 total score (M2) Per additional unit – 1.12 (1.00–1.25) 0.042
Notes: n refers to the number of patients with relapse in each category; N refers to the total number of patients in remission at month 2 in each category. aglobal P=0.703. 
Abbreviations: M2, month 2; PDQ-5, 5-item Perceived Deficit Questionnaire; PHQ-9, 9-item Patient Health Questionnaire.
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The odds of experiencing relapse at month 6 were signifi-
cantly higher for male patients and patients who were married 
or living as a couple. Each additional unit of PDQ-5 total 
score (range 0–20) at 2 months was associated with a 12% 
increase in the odds of relapse at 6 months (P=0.042). Each 
additional unit of PHQ-9 total score (range 0–27) at 2 months 
was associated with a 27% increase in the odds of relapse at 
6 months (P=0.030). The standardization process to account 
for the difference in metrics between the two scales showed 
an additional 0.5 SD in PDQ-5 total score (2.16 units) and 
PHQ-9 total score (1.18 units) at 2 months to be associated 
with a similar increase in the odds of relapse at 6 months.
The results of the supportive analysis using a forward-
selection process were identical to those obtained using 
the backward-selection process (base-case analysis). The 
same factors were retained by both selection processes. The 
ORs for association with PDQ-5 and PHQ-9 scores were 
consistent across all alternative definitions of remission 
and relapse tested, ranging from 1.07–1.14 and 1.08–1.33, 
respectively (Figures S1 and S2). The only two factors 
among those initially selected that had P-values between 0.05 
and 0.10 when they were removed from the multivariate 
models during the backward-selection process were suicide 
attempt before baseline or up to month 2 (P=0.0844) and 
SF-12 PCS score at month 2 (P=0.0667) (Table S2).
Discussion
Results of this study suggest that different sociodemographic 
and clinical factors may be associated with failure to achieve 
remission compared with relapse in patients with MDD. Base-
line sociodemographic and clinical factors that appeared to be 
associated with a reduced likelihood of achieving remission at 
month 2 were severity of depression (assessed by PHQ-9 total 
score), obesity, longer duration of depression, being in psy-
chotherapy, and sexual dysfunction. The finding that baseline 
severity of depression and longer duration of depression were 
associated with the likelihood of remission was expected.15,21,68 
Other studies have also suggested that overweight or obese 
patients may be less likely to achieve remission of MDD.50
The finding that baseline sexual dysfunction increased the 
likelihood of failing to achieve remission was more unex-
pected. Although sexual dysfunction is known to be linked 
to serotonergic neurotransmission and to be associated with 
depression and antidepressant treatment, sexual dysfunction 
may also be a trigger for depression.69,70 Our finding could 
support this hypothesis. If sexual dysfunction plays a role 
in the onset of depression, then it is reasonable to assume 
that it will be associated with the prognosis; however, this 
clearly requires confirmation in further studies. In patients on 
antidepressant therapy, low adherence related to treatment-
emergent sexual dysfunction can also be hypothesized.69,71
The finding that current psychotherapy was associated 
with a lower likelihood of remission at 2 months was also 
unexpected. However, in the context of this analysis, being 
in psychotherapy should be considered as a patient charac-
teristic indicating chronicity of depression or more complex 
disease (such as double depression or depression associated 
with personality disorders), rather than as a treatment inter-
vention. This was supported by results of complementary 
analyses undertaken to explore this finding (Table S3). The 
observed association between country and likelihood of 
achieving remission is difficult to interpret, as it might stem 
from many different sources, including differences in clinical 
practice among participating countries, such as differences 
in the proportion of patients treated by psychiatrists and the 
type of antidepressant received.
Factors that appeared to be associated with an increased 
likelihood of relapse at month 6 in patients in remission at 
month 2 in this study were male sex, being married or liv-
ing as a couple, residual depressive symptoms, and residual 
patient-reported cognitive symptoms. The role of sex as a 
factor associated with relapse in MDD remains uncertain, 
with previous studies yielding conflicting data.21,22,27,64 
The relationship between marital status and depression is 
also complex; however, previous studies have shown low 
relationship satisfaction to be a risk factor for depression, 
which might explain the observed association between being 
married or living as a couple and relapse in this study.72–74
With regard to the association of higher PHQ-9 total score 
with increased likelihood of relapse, it is well documented that 
residual depressive symptoms after remission are associated 
with an increased risk of subsequent relapse in patients with 
MDD.29,66,75 It is not known how cognitive symptoms may 
influence clinical outcome in patients with MDD. Recent data 
suggest that cognitive impairment is a frequent residual symp-
tom of MDD and a principal mediator of occupational impair-
ment in patients in remission.76,77 Residual cognitive symptoms 
may also lead to persistent psychosocial impairment, or cogni-
tive dysfunction may be associated with a cognitive affective 
bias.30 Cognitive symptoms might also impair adherence to 
treatment; however, data on this topic are lacking.
To our knowledge, this is the first demonstration that 
residual patient-reported cognitive symptoms may be associ-
ated with subsequent relapse in patients with MDD. In this 
analysis, each additional unit of PDQ-5 total score at month 
2 was associated with a 12% increase in the odds of relapse 
at month 6. The magnitude of effect for residual patient-
reported cognitive symptoms at month 2 was comparable to 
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that of depressive symptoms at month 2 when expressed in 
terms of a change of 0.5 SD to account for the difference in 
metrics between the PDQ-5 and PHQ-9 scales (range 0–20 
and 0–27, respectively). The extensive control for known 
factors associated with relapse in the final model and the 
supportive analyses demonstrate the consistency of these 
findings. These results need to be confirmed in further studies 
using objective tests of cognitive function. However, these 
findings suggest a role for assessment of cognitive function – 
even with simple questions and in all settings, including 
primary care practices – to identify patients at higher risk 
of subsequent relapse after remission of MDD. While these 
results confirm that residual mood symptoms are a good 
target for detection of patients at risk of relapse of MDD,78,79 
they also imply that therapeutic interventions that reduce 
residual cognitive dysfunction in patients with MDD who 
achieve remission could potentially lead to reduced risk of 
relapse. However, this requires confirmation in further studies 
before definitive recommendations can be made.
In this study, the remission rate at month 2 was 29.7%; 
this is lower than typically reported in clinical trial set-
tings, but is in line with the remission rate reported in more 
naturalistic studies, such as STAR*D.13 The relatively low 
remission rate highlights the fact that achieving remission is 
still a major unmet need for patients with MDD. The relapse 
rate at 6 months in this study was 19.7%, which is lower than 
that reported in STAR*D.13 However, this may be at least 
in part due to the fact that there was only a 4-month interval 
between assessment of remission and relapse in this study; 
relapse rates are more typically assessed up to 6 months after 
achieving remission in clinical trials. An interesting next step 
will be to analyze relapse rates over longer follow-up.
Remission and relapse needed to be precisely defined in 
this study. Composite definitions relying on several different 
assessments were used to increase the likelihood of capturing 
remission and relapse, and to minimize the impact of miss-
ing data. PHQ-9 total score was chosen as the first criterion 
for these composite definitions. The PHQ-9 is a brief, self-
administered questionnaire specifically developed for evalu-
ation of the severity of depressive symptoms,32 and is widely 
used in both research settings and clinical practice. PHQ-9 
total score was assessed for all patients in the study, regard-
less of the setting (primary or specialized care). The second 
criterion used was MADRS total score.34 The MADRS is 
widely used to assess depression severity in randomized 
clinical trials of antidepressant therapy.80,81 This scale requires 
training to ensure reliable scoring, and was thus administered 
only by psychiatrists in this study; however, the majority of 
patients (83.6%) were enrolled and followed up by general 
practitioners. The investigator-administered CGI-S was the 
final criterion for the composite definitions of remission and 
relapse; however, CGI-S score was only used if data were 
unavailable for both of the previous scales, as this assessment 
scale is not specific for depression. The composite definition 
of relapse included an additional criterion related to need for 
treatment modification for lack of efficacy at the 6-month 
visit. This criterion was added to capture the clinical evalu-
ation of the physician, and is commonly used in definitions 
of relapse in relapse-prevention clinical trials.
Cutoff values for remission based on MADRS and CGI-S 
scores are well established.44-46,82 In contrast, several differ-
ent cutoff values have been proposed for remission on the 
PHQ-9 scale. A PHQ-4 total score 5 has been used to define 
remission in some observational studies.56,83,84 However, this 
is based on the theoretical absence of depressive symptoms at 
this score, rather than an accepted definition of remission.32,85 
Validation studies of the PHQ-9 scale established a score 
of 10 or higher as the cutoff for a diagnosis of depression.32 
A recent meta-analysis found the PHQ-9 to have acceptable 
diagnostic properties for detecting MDD for cutoff scores 
between 8 and 11.86 However, the scale was found to be 
sensitive to clinical setting, which could affect the number 
of false positives and thus necessitate adapting the PHQ-9 
cutoff used for remission in individual studies. Available data 
indicate an optimal threshold to define remission of between 
7 and 12 on the PHQ-9 when compared with the CGI-S, and 
between 9 and 13 when compared with the MADRS, sup-
porting the selected cutoff of 9 for the definition of remission 
used in this study. Indeed, this cutoff value has been used in 
other studies.87,88 With this definition, there is no gap between 
remission and relapse on the PHQ-9. To test if this induces a 
risk of misclassification of patients that could lead to biased 
estimates, additional supportive analyses using alternative 
definitions of remission and relapse were undertaken for the 
current study; using different thresholds yielded similar ORs 
for PDQ-5 and PHQ-9 effect at month 6.
A key strength of this study is that it was performed in 
a real-world setting with longitudinal follow-up of a large 
cohort of patients, the majority of whom were enrolled and 
followed up by primary care physicians. This suggests that 
the study findings are applicable to routine clinical practice, 
where patients with MDD are typically treated in primary 
care settings. In addition, the analysis was based on vari-
ables identified from a literature review as being clinically 
relevant factors. The literature review yielded concepts and 
notions that we tried to capture using available PERFORM 
data. For example, substance abuse is captured both by the 
tobacco-use covariate and the concomitant mental disorder 
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covariate. Some variables were added to the list of covariates, 
as they were considered important for the outcome of the 
disease (eg, disease management and important life events). 
Country, age, sex, and PHQ-9 total score (at baseline for the 
remission analysis and at month 2 for the relapse analysis) 
were forced into the model as adjustment variables, because 
they were identified as potential confounders. The effects of 
treatment in the study population were addressed via cova-
riates reflecting the type of treatment (psychotherapy) and 
meaningful treatment patterns (treatment switch, treatment 
stop, and line of treatment). The drug received was not taken 
into account, as the study design and data-collection method 
did not allow for assessment of treatment effect.
A potential limitation is the fact that the PHQ-9 is 
completed by patients, while the MADRS and CGI-S are 
completed by physicians, which may have introduced differ-
ences in estimation of rates of remission and relapse between 
the different measures. For analysis of factors associated 
with relapse in patients who were in remission at month 2, 
fewer variables were selected from the univariate analysis; 
this is most likely due to the relatively limited sample size. 
Nevertheless, results of the supportive analyses using the 
forward-selection process were consistent with the ORs 
obtained using the backward-selection process, confirming 
the robustness of the statistical model. Regarding relapse, 
it is important to note that this study was observational and 
differs in design from relapse-prevention trials. In particular, 
there was only a 4-month interval between assessment of 
remission and relapse in this study. In addition, cognitive 
dysfunction was assessed using a patient-reported question-
naire, and little has been published regarding the extent to 
which PDQ-5 score reflects or is correlated with objective 
measures; however, this is relevant from a routine-practice 
perspective, as objective neuropsychological tests are not 
used in primary care settings.
Conclusion
In summary, results of this large observational study suggest 
that certain sociodemographic and clinical characteristics 
may be associated with an increased likelihood of failure to 
achieve remission in patients with MDD or with subsequent 
relapse in patients who do achieve remission. In particular, 
cognitive dysfunction appears to be an easily measurable 
patient characteristic that may be associated with an increased 
likelihood of relapse at 6 months in patients who have 
achieved remission. This finding suggests that therapeutic 
interventions that reduce residual cognitive dysfunction in 
patients who achieve remission could lead to a reduced risk 
of relapse of MDD. Further studies are needed to confirm 
this and to provide evidence on the magnitude of the effect 
and its importance for clinical practice.
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Table S1 Details of backward-selection process for analysis of factors associated with remission at month 2
Step Factors in model Factor removed OR (95% CI) P-value AIC BIC
0 23 – – – 684.158 815.460
1 22 at least one other concomitant mental disorder 1.00 (0.52–1.92) 0.9910 682.158 809.083
2 21 Chronic pain or fibromyalgia 1.03 (0.57–1.88) 0.9185 680.169 802.717
3 20 sF-12 – mental health (Mcs) 1.00 (0.97–1.04)a 0.8809 678.191 796.363
4 19 Tobacco use 1.09 (0.71–1.68) 0.6871 676.353 790.148
5 18 sick leave within the 12 months before baseline 0.87 (0.55–1.36) 0.5348 674.740 784.158
6 17 at least one chronic medical condition 0.82 (0.50–1.34) 0.4278 673.373 778.415
7 16 switch of antidepressant 1.24 (0.73–2.10) 0.4253 672.004 772.669
8 15 hospitalization for depression during the 12 weeks before baseline 0.58 (0.15–2.28) 0.4336 670.671 766.959
9 14 sF-12 – physical health (Pcs) 1.01 (0.99–1.03)a 0.2907 669.792 761.703
10 13 WPai – percentage activity impairment due to problem 1.01 (1.00–1.02)a 0.1753 669.654 757.188
11 12 PDQ-5 total score 0.97 (0.91–1.02)a 0.2426 669.020 752.178
12 11 living area 1.37 (0.89–2.12)b 0.1502 669.082 747.863
13 10 cgi-s 0.85 (0.70–1.04)a 0.1127 669.574 743.978
14 9 educational level (4 categories) 1.67 (0.95–2.94)c 0.1277 669.435 730.709
14 9 educational level (4 categories) 1.82 (0.92–3.59)d – – –
14 9 educational level (4 categories) 1.95 (1.09–3.48)e – – –
15 8 suicide attempt – before baseline 0.44 (0.18–1.04) 0.0624 671.406 728.304
Notes: acontinuous factor; brural vs urban; chigh school vs no degree or diploma/elementary school; dnon-university degree vs no degree or diploma/elementary school; 
euniversity degree vs no degree or diploma/elementary school.
Abbreviations: aic, akaike information criterion; Bic, Bayesian information criterion; cgi-s, clinical global impressions–severity of illness; Mcs, mental component 
summary; PCS, physical component summary; PDQ-5, 5-item Perceived Deficit Questionnaire; SF-12, 12-item Short-Form Health Survey; WPAI, Work Productivity and 
activity impairment.
Supplementary materials
Backward selection (base-case analysis)a
Forward selectiona
Remission threshold: PHQ-9 score =6b
Remission threshold: PHQ-9 score =7b
Remission threshold: PHQ-9 score =8b
Relapse threshold: PHQ-9 score =11b
Relapse threshold: PHQ-9 score =12b
Relapse threshold: PHQ-9 score =13b
Minimum δ PHQ-9 score =3b,c
Minimum δ PHQ-9 score =5b,c 1.09 (0.97–1.22)
1.10 (0.98–1.23)
1.10 (0.98–1.22)
1.10 (0.99–1.23)
1.12 (0.99–1.27)
1.14 (1.01–1.28)
1.08 (0.97–1.20)
1.08 (0.97–1.20)
1.09 (0.97–1.22)
1.07 (0.93–1.24)
1.12 (1.00–1.25)
1.11 (0.92–1.34)
1.12 (1.00–1.25)
Minimum δ PHQ-9 score =2b,c
Minimum δ PHQ-9 score =4b,c
MADRS before PHQ-9b
0 0.5 1
Odds ratio
1.5
Figure S1 summary of supportive analyses of PDQ-5 effect on relapse at month 6.
Notes: acomputed for patients with complete values on all candidate variables (n=186); bcomputed for patients with complete values on all variables in the final model 
(n=193); cadditional criterion for relapse definition: minimum change in PHQ-9 total score between month 2 and month 6. Values expressed as OR (95% CI).
Abbreviations: MaDrs, Montgomery–Åsberg Depression rating scale; PhQ-9, 9-item Public health Questionnaire.
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Table S2 Details of backward-selection process for analysis of factors associated with relapse at month 6 for patients in remission at 
month 2
Step Factors in model Factor removed OR (95% CI) P-value AIC BIC
0 12 – – – 178.837 230.449
1 11 WPai – percentage activity impairment due to problem (M2) 1.00 (0.97–1.03) 0.9937 176.837 225.223
2 10 switch of antidepressant at baseline, between baseline and M2, 
or at M2 (up to M2)
1.48 (0.56–3.92) 0.4349 175.437 220.598
3 9 sF-12 – mental health (Mcs – M2) 0.97 (0.92–1.03) 0.3213 174.428 216.362
4 8 cgi-s (M2) 1.40 (0.92–2.13) 0.1087 175.093 213.802
5 7 suicide attempt before baseline or between baseline and M2  
(up to M2)
4.61 (0.83–25.51) 0.0844 175.981 211.464
6 6 sF-12 – physical health (Pcs – M2) 0.96 (0.92–1.00) 0.0667 177.333 209.591
Abbreviations: aic, akaike information criterion; Bic, Bayesian information criterion; cgi-s, clinical global impressions–severity of illness; M2, month 2; Mcs, 
mental component summary; PCS, physical component summary; PDQ-5, 5-item Perceived Deficit Questionnaire; SF-12, 12-item Short-Form Health Survey; WPAI, Work 
Productivity and activity impairment.
Figure S2 summary of supportive analyses of PhQ-9 effect on relapse at month 6.
Notes: acomputed for patients with complete values on all candidate variables (n=186); bcomputed for patients with complete values on all variables in the final model 
(n=193); cadditional criterion for relapse definition: minimum change in PHQ-9 total score between month 2 and month 6. Values expressed as OR (95% CI).
Abbreviations: MaDrs, Montgomery–Åsberg Depression rating scale; PhQ-9, 9-item Public health Questionnaire.
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remission and relapse in MDD
Table S3 Complementary analysis comparing factors identified as potential indicators of severity and chronicity of depression 
according to psychotherapy at baseline
Factor Psychotherapy (n=158) No psychotherapy (n=954) P-valuea
Is the current episode the patient’s first depressive episode?
Yes
No
60 (38.2%)
97 (61.8%)
425 (44.6%)
528 (55.4%)
0.135 (χ2)
if no:
Previous psychotherapy
Yes
Did your patient achieve remission after this episode?
Yes
Has the patient been hospitalized for depression?
Yes
Has the patient ever attempted suicide?
Yes
67 (69.1%)
77 (79.4%)
13 (13.4%)
15 (15.5%)
159 (30.2%)
442 (83.7%)
42 (8.0%)
70 (13.3%)
0.001 (χ2)
0.296 (χ2)
0.082 (χ2)
0.560 (χ2)
Time since beginning of this depressive episode (3 categories)
4 weeks
4–8 weeks
8 weeks
33 (20.9%)
38 (24.1%)
87 (55.1%)
284 (29.8%)
186 (19.5%)
482 (50.6%)
0.058 (χ2)
Patient considered “difficult to treat” or “treatment-resistant”?
Yes 33 (20.9%) 112 (11.8%) 0.002 (χ2)
is the current depressive episode already being treated with  
an antidepressant (prior to this visit)?
Yes 41 (25.9%) 200 (21.0%) 0.163 (χ2)
at least one chronic medical condition
Yes 41 (25.9%) 254 (26.6%) 0.859 (χ2)
at least one important life event
Yes 74 (54.8%) 386 (48.7%) 0.192 (χ2)
PhQ-9 total score
Mean ± sD 18.1±5.2 17.5±5.4 0.311
cgi-s
Mean ± sD 4.4±1.1 4.1±1.0 0.003
Note: aχ2 test or Fisher’s exact test for categorical variables, student’s t-test for continuous variables.
Abbreviations: cgi-s, clinical global impressions–severity of illness; PhQ-9, 9-item Patient health Questionnaire.
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